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the BceAB--like systems, which frequently provide a high level of resistance against peptide 23 antibiotics that target intermediates of the lipid II cycle of cell wall synthesis. How a transporter can 24 offer protection from drugs that are active on the cell surface, however, has presented researchers 25 with a conundrum. Multiple theories have been discussed, ranging from removal of the peptides 26 from the membrane, internalisation of the drug for degradation, to removal of the cellular target 27 rather than the drug itself. To resolve this much--debated question, we here investigated the mode 28 of action of the transporter BceAB of Bacillus subtilis. We show that it does not inactivate or import 29 its substrate antibiotic bacitracin. Moreover, we present evidence that the critical factor driving 30 transport activity is not the drug itself, but instead the concentration of drug--target complexes in the 31 cell. Our results, together with previously reported findings, lead us to propose that BceAB--type 32 transporters act by transiently freeing lipid II cycle intermediates from the inhibitory grip of 33 antimicrobial peptides, and thus provide resistance through target protection of cell wall synthesis. 34
Target protection has so far only been reported for resistance against antibiotics with intracellular 35 targets, such as the ribosome. However, this mechanism offers a plausible explanation for the use of 36 transporters as resistance determinants against cell wall--active antibiotics in Gram--positive bacteria 37 where cell wall synthesis lacks the additional protection of an outer membrane. 38
The bacterial cell wall and its biosynthetic pathway, the lipid II cycle, are important targets for 40 antibiotics, especially in Gram--positive bacteria that lack the protective layer of the outer 41 membrane. Cell wall--targeting drugs include antimicrobial peptides (AMPs), which bind to cycle 42 intermediates and prevent biosynthetic enzymes from carrying out the next reaction (1). It is hardly 43 surprising that bacteria have developed a plethora of strategies to protect themselves against such 44 antibiotic attack. Among the many known resistance mechanisms, a common strategy is the 45 production of ATP--binding cassette (ABC) transporters that presumably remove AMPs from their site 46 of action (2, 3). A major group of these are the BceAB--type transporters, which are found in many 47 environmental and pathogenic species of the phylum Firmicutes (4). The eponymous and to date 48 best--characterised system is BceAB of Bacillus subtilis (5). BceAB--type transporters comprise one 49 permease (BceB) and two ATPases (BceA) (BceA, 6) . The permeases consist of ten transmembrane 50 helices and a large extracellular domain that is thought to contain the ligand binding region of the 51 transporter (7, 8) . Transporter production is regulated via a two--component regulatory system (TCS)  52 consisting of a histidine kinase (BceS) and a response regulator (BceR) (BceR, 5, 7) . A striking feature 53 of these systems is that signalling is triggered by the activity of the transporter itself (9). Due to this 54 flux--sensing strategy, signalling is directly proportional to transport activity, and the transporter 55 effectively autoregulates its own production ( Fig. 1A) . 56
Considering the relevance of BceAB--like systems among Firmicutes bacteria, we here set out to 89 address the controversial question on their mode of action and how a transporter can provide 90 effective protection against cell surface--active antibiotics. Using a peptide release assay, we exclude 91 that BceAB acts by import or inactivation of bacitracin. Based on the discovery that signalling within 92 the Bce system is directly proportional to transport activity, we established a promoter--reporter 93 assay as a proxy for transport activity. Our results show that the critical variable in determining 94 transport activity of BceAB is bacitracin in complex with its cellular target UPP, rather than bacitracin 95 or the lipid carrier alone. Taking together the findings of this study and the literature, we conclude 96 that BceAB--type transporters appear to transiently free their cellular target from the inhibitory grip 97 of the AMP and provide resistance via target protection of cell wall synthesis. 98 99
METHODS

100
Bacterial strains and growth conditions. 101
All strains used in this study are given in Table 1 . E. coli and B. subtilis strains were routinely grown at 102 37 °C with agitation (180 rpm) in lysogeny broth (LB) medium. Solid media contained 1.5% (w/v) 103 agar. Selective media contained ampicillin (100 µg ml --1 ), chloramphenicol (5 µg ml --1 ), kanamycin (10 104 µg ml --1 ), spectinomycin (100 µg ml --1 ), tetracycline (10 µg ml --1 ) or erythromycin (1 µg ml --1 ) with 105 lincomycin (25 µg ml --1 ; macrolide--lincosamide--streptogramin B; mls). For full induction of the 106 promoter P xylA , xylose was added to a final concentration of 0.2 % (w/v). Bacterial growth was 107 routinely monitored as optical density at 600 nm wavelength (OD 600 ) measured 108 spectrophotometrically in cuvettes of 1 cm light path length. 109 cultures of recipient strains were grown in 500 µl Paris medium (6.1 mM K 2 HPO 4 , 4.4 mM KH 2 PO 4 , 114 0.4 mM trisodium citrate, 1 % (w/v) glucose, 20 mM potassium L--glutamate, 0.1 % (w/v) casamino 115 acids, 3 mM MgSO 4 , 25 µg ml --1 tryptophan, 8 µM ferric ammonium citrate) at 37 °C with aeration 116 (180 rpm) . Day cultures (500 µl) were inoculated 1:50 in fresh, pre--warmed Paris medium and grown 117 for three hours (37 °C, 180 rpm). To each culture, 50 µl of isolated genomic DNA (gDNA) of the donor 118 strain, or 0.5--1 µg of isolated plasmid DNA were added. Transformation cultures were grown for five 119 more hours and plated on selective media. For mls or chloramphenicol resistance, cultures were pre--120 induced for one hour at 1:40 of the final concentration of the respective antibiotic. Donor strain 121 gDNA was isolated by mixing an overnight culture of the donor 1:1 with SC buffer (150 mM NaCl, 10 122 mM sodium citrate, pH 7.0) and harvesting the cells by centrifugation (5 min, 1300  g). The pellet 123 was resuspended in SC buffer and incubated with lysozyme at 37 °C for 15 minutes. The solution was 124 mixed 1:1 with 5 M NaCl and passed through a 0.45 µm syringe--driven filter. Plasmid DNA was 125 isolated from E. coli using conventional mini--prep kits. 126
To create a construct for inducible expression of bcrC, the gene was PCR--amplified from B. subtilis 127 W168 using primers TM2731 and TM2732, which incorporated prefix and suffix, respectively, of the 128 modified 'Freiburg standard' of BioBrick cloning described previously (16). The resulting fragment 129 was cloned into pSB1A3 via the EcoRI and PstI restriction sites (pJNESB101). The bcrC gene was then 130 re--excised using XbaI and PstI. Assembly with an EcoRI/SpeI fragment of the BioBrick carrying the 131 xylose--inducible promoter P xylA (16) into EcoRI/PstI digested pBS2E resulted in the inducible P xylA --bcrC 132 construct pJNE2E01. A transcriptional P psdA --lux reporter construct (pSDlux102) was created by PCR 133 amplification of the promoter region of psdAB of B. subtilis using primers TM0599 and TM2242, and 134 ligation with pAH328 via EcoRI and NotI restriction sites. The existing P bceA --luxABCDE reporter 135 (pSDlux101; (17) was re--constructed in vector pBS3Elux (18), which contains an mls resistance 136 marker instead of chloramphenicol. This was achieved by PCR amplification of the promoter 137 fragment with primers SG843 and SG883, and cloning via EcoRI and PstI sites, resulting in plasmid 138 pMG3Elux1. 139 140
Determination of the minimal inhibitory concentration 141
The susceptibility of B. subtilis strains to bacitracin was determined using the minimal inhibitory 142 concentration (MIC) determined by broth micro--dilutions. For this, two--fold serial dilutions of Zn 2+ --143 bacitracin were prepared in 2 ml of Mueller--Hinton medium and inoculated 1:500 from overnight 144 cultures grown in the same medium. For higher resolution, in some instances defined concentrations 145 of Zn 2+ --bacitracin were added directly to each culture. Cultures were incubated overnight (37 °C, 146 180 rpm) and examined for growth after 24 h. The MIC was determined as the lowest concentration 147 at which no visible growth was detected. All experiments were performed in at least biological 148 triplicates, and mean values and standard deviations were calculated to report the data. 149 150
Bacitracin uptake assays 151
Bacitracin uptake was assayed with slight modification to previously described protocols (19, 20) . 152
Overnight cultures were diluted 1:500 in 100 ml LB supplemented with 1 % (w/v) fructose. To induce 153
BceAB production in the wild type, 1 μg ml --1 bacitracin was added at the time of inoculation. The 154 cultures were incubated for 3.5--4.75 h at 37 °C (200 rpm) until they reached an OD 600 of 1.0--2.0. Cells 155 were harvested by centrifugation (4000  g, 10 minutes, room temperature) and washed twice with 156 50 mM potassium phosphate (pH 7--7.5) and 100 mM NaCl. Cell density was adjusted to an OD 600 of 157 10 in assay buffer (50 mM potassium phosphate (pH 7--7.5), 100 mM NaCl, 1 % (w/v) fructose and 50 158 μM zinc sulfate). Aliquots of 2.4 ml of the cell suspension were incubated for 10 minutes at 37°C 159 (200 rpm). Bacitracin was added to a final concentration of 5 μg ml --1 , followed by incubation for 30 160 minutes at 37 °C (200 rpm). As control, one sample containing no cells received the identical 161 treatment. Cells were removed by centrifugation (4000  g, 10 minutes, room temperature) and the 162 supernatants were filtered (0.45 µm). The supernatants were stored for no longer than five days at --163 20 °C, and were concentrated 5--fold using an Eppendorf Concentrator 5301 speed vacuum at room 164 temperature. 165
To quantify the bacitracin remaining in the culture supernatants, the sensitivity of the strain TMB713 166 was exploited in a bioassay adapted from the method established by K. Okuda et al. (21) . To this 167 end, an overnight culture of TMB713, grown in LB with selective antibiotics, was diluted 1:30 into 3 168 ml melted (60 °C) LB soft agar (0.75 % (w/v)) and poured evenly onto a dried LB agar plate, allowed 169 to solidify 10 minutes at room temperature and then dried for 10 minutes. Plugs 6 mm in diameter 170 were removed from the plate, leaving stable holes in the agar. In volumes of 50 μl, bacitracin 171 standards (5--50 μg ml --1 ) and concentrated supernatants were applied into the holes and plates were 172 immediately incubated upright at 37°C. After 24--26 hours, the diameter of the growth inhibition 173 zone was measured. Clearing zones measured from bacitracin standards were used to create a 174 standard curve. Bacitracin concentrations in supernatants were extrapolated using the standard 175 curve and worked back to the original sample from the known 5--fold concentration factor during 176 sample preparation. 177 178
Computational model and simulations 179
Model predictions for the data in figures 3 and 4 were performed with a previously established 180 model for the lipid II cycle and its interaction with the bacitracin stress response network in B. 181 subtilis (22, 23) . Briefly, the model uses deterministic differential equations to describe the time--182 dependent concentrations of the different lipid II cycle intermediates, as well as the bacitracin stress 183 response modules BcrC and BceAB. A detailed description of the model assumptions and equations 184 for the bacitracin resistance network in B. subtilis wild type and the DbcrC mutant has been laid out 185 before (23). In the model for the DbcrC mutant, a homeostatic up--shift in de novo synthesis of UPP 186 leads to maintenance of PG synthesis to ensure bcrC deletion is not lethal (23). This additional 187 increase in carrier pool exacerbates the accumulation of UPP even further. To illustrate the model 188 behavior for a bcrC overexpression strain ( Fig. 4B ), we assumed that this strain features a 1.5--fold 189 stronger UPP phosphatase activity compared to wild--type cells, based on the higher activity of the 190 P xylA promoter driving bcrC expression in this strain (9) relative to the native P bcrC promoter (24). All 191 numerical simulations of the differential equations were performed with custom scripts developed 192 in MATLAB TM software (The MathWorks, Inc.). 193 194
Luciferase reporter assay 195
For reporter gene assays, 10 ml of LB or modified chemically defined medium (MCSE, as described in 196 16) were inoculated 1:1000 from overnight cultures of each strain to be tested. Day cultures were 197 grown at 37 °C with agitation (180 rpm) to an OD 600 of around 0.5, to ensure exponential growth. 198
Cultures were then diluted into fresh growth medium to an OD 600 of 0.01 and distributed into 96 199 well microplates (Corning®, black, clear flat bottom), with 100 µl culture volume per well. Wells 200 around the plate edge were filled with water to reduce evaporation. Luciferase activity of strains was 201 determined in a Tecan® Spark® microplate reader controlled by the SparkControl™ software (Tecan 202
Trading AG, Switzerland). Cells were grown in the microplate reader for 5 hours with continuous 203 shaking incubation (37 °C, 180 rpm, orbital motion, amplitude: 3 mm). After one hour of incubation, 204 cells were challenged with varying concentrations of antibiotic. The OD 600 and luminescence (relative 205 luminescence units, RLU) were measured every 5 minutes (integration time: 1000 ms). 206
Luminescence output was normalized to cell density by dividing each data point by its corresponding 207 blank--corrected OD 600 value (RLU OD --1 ). For dose response curves, RLU OD --1 values were determined 208 from the average of three data points taken at steady--state (25, 30 and 35 min). Experiments were 209 carried out at least in biological triplicates. To determine the dose response behaviour of strains for 210 bacitracin, luminescence values were normalised, with 0 % defined as the lowest, and 100 % as the 211 highest measured RLU OD --1 value for each strain. Data were then fitted with variable slope dose--212 response curves in GraphPad Prism7, using the logarithms of bacitracin concentrations as x, and 213 normalised luminescence as y values, and applying default settings. Statistical comparison of the 214 resulting EC 50 values was performed using the in--built comparison tool for non--linear regression fits 215 of GraphPad Prism 7, based on an extra sum--of--squares F test.
216
RESULTS AND DISCUSSION
217
BceAB does not import or inactivate bacitracin. 218
To investigate the resistance mechanism of BceAB--type transporters, we first focussed on the 219 direction of transport by BceAB. To this end, we applied a modified version of the peptide release 220 assay established by Otto and colleagues (19) . This is based on quantification of the AMP 221 concentration that remains in the culture supernatant after incubating cell suspensions of bacteria 222 carrying or lacking the transporter in an AMP--containing buffer. Presence of an importer should lead 223 to a decrease in the AMP concentration remaining in the buffer, while an increase in AMP 224 concentration compared to transporter--negative cells would be indicative of a mechanism where the 225 drug is expelled from the bacterial cell envelope (19, 20) . To quantify the remaining bacitracin, we 226 chose a bioassay--based method, similar to the technique reported by Okuda and colleagues (21, see 227 methods for details) . This would allow us to determine the amount of biologically active peptide 228 remaining, to provide additional information on whether the action of BceAB may somehow 229 inactivate the antibiotic. 230
Earlier models for BceAB action considered bacitracin import, potentially followed by intracellular 231 degradation (7). Alternative conceivable mechanisms of resistance could be inactivation of the 232 extracellular AMP, e.g. through shedding of phospholipids, which could be catalysed by BceAB, akin 233 to a mechanism reported for daptomycin resistance in S. aureus (25). However, our bio--assay 234 methodology did not show any significant reduction in bacitracin activity by BceAB--containing cells 235 (i.e. wild--type cells that had been pre--induced with low concentrations of bacitracin to ensure bceAB 236 expression), arguing against such mechanisms (Fig. 2 ). We observed a slight reduction in active 237 bacitracin compared to the starting concentration of 5 µg ml --1 , but this applied to all samples, 238
including the buffer--control. Therefore, it was likely due to the known oxidative deamination of 239 bacitracin A to bacitracin F, which lowers the antimicrobial activity (26), during incubation and 240 sample processing. Our data thus indicate that BceAB neither imports bacitracin into the cell, nor 241 inactivates or degrades bacitracin in the extracellular space. 242
When we compared BceAB positive and negative cells, we could not detect significant differences in 243 supernatant concentrations of the drug (Fig. 2 ). This was not in line with our hypothesis that BceAB 244 should expel bacitracin from the membrane into the extracellular milieu. In a recent study on the 245 BceAB--type transporter NsrFP from Streptococcus agalactiae COH1, which used a similar peptide 246 release assay, the residual AMP concentration in the culture supernatant was significantly higher in 247 an nsrFP + strain compared to strains with no or inactive NsrFP, in agreement with a 'hydrophobic 248 vacuum cleaner' mechanism as proposed for BceAB (27). The main difference to our study was that 249
the NsrFP experiments were done using the lantibiotic nisin as substrate, and earlier similar studies 250 had also used lantibiotic substrates (19, 20, 28) . As lantibiotics and bacitracin have fundamentally 251 different modes--of--action, we believe that the peptide release assay may not have been sensitive 252 enough to detect small differences in the amount of bacitracin attached to the cells. 253
Nevertheless, based on the homology between BceAB and NsrFP, it is plausible that both employ the 254 same functional mechanism (27). Further support for the expulsion of AMPs from the membrane is 255 provided by the LanFEG--type transporters, which use such a strategy to confer self--immunity in 256
AMP--producing bacteria. Well--known examples of this group include the transporters NisFEG of 257
Lactococcus lactis and SpaFEG of B. subtilis (2). Several studies have shown that these transporters 258 effectively mediate resistance against AMPs without degrading or inactivating the drugs, but by 259 releasing them into the culture supernatant (19, 20, 28, 29) . Although LanFEG transporters share no 260 close evolutionary relationship with BceAB--type systems (2), the fact that they impart resistance 261 against the same range of antibiotics lends weight to the hypothesis that both use a similar principle 262 of protection. 263
BceAB--type systems belong to the Type VII ABC transporter superfamily, of which the E. coli 264 macrolide resistance transporter MacB is the paradigm example (30). MacB was recently shown to 265 act according to a molecular bellows mechanism and expel its substrate from the periplasm across 266 the outer membrane via the TolC exit duct by undergoing extensive conformational changes in its 267 periplasmic domain (31). This mode of 'transport', which does not involve physical movement of a 268 substrate across a membrane but instead uses intracellular ATP hydrolysis to perform mechanical 269 work in the periplasm, was termed 'mechanotransmission' (31). BceAB shares the critical features of 270
MacB that are required for the mechanotransmission mechanism (30). In this case, the work carried 271 out by the transporter would be to shift the equilibrium of the bacitracin binding reaction from the 272 membrane more towards the extracellular environment. For such a 'hydrophobic vacuum cleaner' 273 mechanism to work, the transporter will need to distinguish between the membrane--bound and the 274 free form of the AMP. Interestingly, bacitracin undergoes an extensive conformational change upon 275 binding its cellular target, from a free state with no clear hydrophobic moment, to an amphipathic, 276 closed dome--shaped conformation when bound to UPP (32). While we have shown previously that 277
BceAB was able to bind bacitracin in vitro, these experiments were carried out with detergent--278 solubilised protein that may have contained co--purified membrane lipids (6). We therefore cannot 279 draw any direct conclusions on whether it interacted with the free drug, or with any bacitracin--UPP 280 complexes (UPP--BAC) that may have been present in the experiment. Therefore, we next aimed to 281 identify the physiological substrate of BceAB in vivo. 282
Exploiting the flux--sensing mechanism as suitable strategy to monitor BceAB activity. 283
To study the function of BceAB in vivo, we first required a strategy to quantify transport activity in 284 living cells. We previously showed that signalling within the Bce system is directly proportional to 285 BceAB transport activity (9). As the signalling cascade ultimately leads to activation of the promoter 286 controlling bceAB expression (P bceA ), the activity of a P bceA --luxABCDE reporter fusion can therefore be 287 taken as a proxy for BceAB activity (Fig. 1A ). Using this approach, we monitored BceAB activity in the 288 wild--type strain carrying the reporter fusion (SGB73, WT) under several sub--inhibitory bacitracin 289 concentrations. In agreement with earlier data (9), the threshold concentration to elicit detectable 290
BceAB activity was 0.03 µg ml --1 bacitracin, and the activity gradually increased until maximum levels 291 were reached at 30 µg ml --1 (Fig. 1B) . As it was previously shown that higher bacitracin 292 concentrations did not cause a further increase in activity (7, 9, 24) , we deemed this concentration a 293 suitable endpoint. 294 295
Accumulation of UPP specifically increases BceAB activity at low bacitracin concentrations. 296
While the preliminary experiment in Fig. 1B showed that transport activity increased with higher 297 bacitracin concentrations, it did not allow us to distinguish between free bacitracin and UPP--BAC as 298 substrates. This is because the concentration of UPP--BAC will change proportionally to the 299 concentration of bacitracin added to the culture (Fig. 1C ). To distinguish whether the critical variable 300 determining BceAB transport activity was bacitracin itself or the UPP--BAC complex, we required a 301 strategy to change the concentration of UPP--BAC, while keeping the concentration of bacitracin 302 constant. Considering the reaction equilibrium between bacitracin and UPP--BAC (Fig. 1C ), this should 303 be possible by adjusting the cellular levels of UPP, as increased amounts of UPP result in higher 304 concentrations of UPP--BAC without altering the bacitracin concentration. 305
To find a suitable genetic approach to change the UPP levels in the cell, we turned to mathematical 306 modelling. Based on the computational description of the lipid II cycle (22), we recently developed a 307 mathematic model that describes the protective effect of the bacitracin resistance determinants 308
BceAB and BcrC of B. subtilis on the progression of the lipid II cycle (23). This model can predict 309 changes to the pool levels of lipid II cycle intermediates under different conditions and suggests that 310 reducing the rate of UPP dephosphorylation increases the level of UPP displayed on the extracellular 311 face of the membrane. In B. subtilis, the dephosphorylation reaction of UPP to UP is catalysed by 312 two phosphatases, . BcrC plays the more prominent role during exponential 313 growth, and bcrC deletion should thus have the bigger effect on reducing the rate of 314 dephosphorylation. In a ∆bcrC scenario, the model predicted the UPP pool to increase more than 315 eight--fold over the wild--type levels (Fig. 3A&B) . 316
To exploit this finding, we deleted bcrC in our reporter strain (∆bcrC). When we re--tested this strain 317 for BceAB activity, we observed a striking 10--fold reduction in the threshold concentration required 318 to trigger detectable transport activity (0.003 µg ml --1 , Fig. 3C ). Likewise, maximum BceAB activity 319 was observed at 0.3 µg ml --1 bacitracin (Fig. 3C, turquoise) , 100--fold less than required to reach a 320 similar activity in the wild type (Fig. 3C, dark blue) . Fitting of a dose--response curve to the 321 normalised data for both strains (see methods for details) showed that indeed the half--maximal 322 effective concentration of bacitracin (EC 50 ), i.e. the concentration where BceAB activity was half its 323 maximum, was shifted from 5.5 µg ml --1 in the wild type to 0.05 µg ml --1 in the ∆bcrC strain (Fig. S1A) . 324 Importantly, the overall shape of the curve was not altered between strains, showing that the 325 differences were solely due to changes in substrate concentration upon UPP accumulation, not any 326 mechanistic changes in the transporter itself that may have been caused by bcrC deletion. To 327 explore if UPP alone could serve as the physiological substrate of BceAB, the activity was also 328 compared in the absence of bacitracin. There was no detectable BceAB activity in either of the 329 tested strains, which suggested that accumulation of UPP alone was not sufficient to trigger 330 transport by BceAB. These findings were a first indication that the critical variable that determines 331
BceAB activity is the concentration of UPP--BAC complexes, rather than bacitracin or UPP alone. 332
In the wild type, induction of P bceA of course not only drives reporter gene expression but also 333 increases the amount of BceAB present in the cell. To exclude that the observed sensitivity shift 334 upon UPP accumulation was not due to changes in bceAB expression, we uncoupled BceAB 335 production from its native regulation. This was achieved by deleting the native copy of bceAB in the 336 reporter strain and introducing an ectopic copy under xylose--inducible control (P xylA --bceAB; strain 337 SGB218). The same was done in the ∆bcrC reporter, resulting in strain SGB677. Comparing BceAB 338 activity in these two strains again showed a marked decrease (30--fold) in the threshold bacitracin 339 concentration required to trigger detectable activity upon accumulation of UPP (Fig. S1B ). This 340
shows that the observed shift in sensitivity of BceAB could not be explained by indirect regulatory 341 effects on bceAB expression. 342
Accumulation of UPP may have caused wider alterations in the cell membrane and/or affected 343
BceAB activity in a non--specific manner, rather than the intended change in the concentration of 344 UPP--BAC complexes. Therefore, we next tested if bcrC deletion also altered BceAB activity in 345 response to AMPs that do not interfere with UPP. To this end, we measured BceAB activity in 346 response to mersacidin and deoxy--actagardine B, two other AMPs that are known substrates for 347 BceAB (8). As both of these peptides target lipid II but not UPP, the complex formation between 348 these AMPs and their respective cellular target should be unaffected by changes in the UPP level. 349
Indeed, our theoretical model predicted that the lipid II pool on the extracellular face of the 350 membrane would remain almost unchanged in a ∆bcrC scenario compared to the wild type ( Fig.  351   3A&B ). This is because the total amount of lipid carrier is homeostatically increased in a bcrC 352 deletion strain to ensure a close--to--optimal rate of peptidoglycan synthesis (23). The model 353 therefore confirms that decreasing the UPP dephosphorylation rate in the ∆bcrC strain specifically 354 causes accumulation of UPP but does not affect other cycle intermediates. 355
As with bacitracin, a gradual increase of BceAB activity was observed with increasing amounts of 356 mersacidin or deoxy--actagardine B, in both the wild type and ∆bcrC strains (Fig. 3D, E) . However, we 357 did not observe any significant differences in threshold substrate concentrations nor overall BceAB 358 activity between the two strains. As an additional control, we tested the activity of a second BceAB--359 type transporter in B. subtilis, PsdAB, which confers resistance against nisin, another lipid II binding 360 AMP (8). PsdAB activity was determined using the same luminescence--based assay principle as for 361
BceAB, but with P psdA activity as a proxy for transport activity. As before, activity increased with nisin 362 concentration in both the wild type and ∆bcrC mutant, but again no significant differences between 363 strains were observed (Fig. 3F) . These findings show that bcrC deletion and concomitant 364 accumulation of UPP did not have a general effect on BceAB or PsdAB function. Instead, BceAB 365 activity appeared to specifically depend on the concentration of UPP--BAC in the membrane. This is 366 consistent with the proposed hypothesis for a 'hydrophobic vacuum cleaner' mechanism of 367 transport, suggesting that the physiological substrate of BceAB is indeed the antibiotic in complex 368 with its cellular target. 369 370
Depletion of UPP affects transport activity on a global level 371
To further explore the effect of altered UPP levels on BceAB activity, we next sought to decrease the 372 pool of UPP displayed on the outer face of the membrane, and hence the amount of UPP--BAC 373 complexes formed. The mathematical model predicted that an increased rate of UPP 374 dephosphorylation, e.g. by overproducing BcrC, may lead to such a decreased UPP pool (Fig. 4A&B) , 375 although differences to the wild type are less pronounced than with bcrC deletion. To realise this 376 experimentally, we overproduced BcrC by placing an additional copy of bcrC under control of the 377 xylose--inducible promoter P xylA (SGB758). Testing the BceAB activities in the strain with reduced UPP 378 levels led to overall lower activity upon addition of bacitracin, and even at the maximal 379 concentration tested the activity was less than 50 % of the wild--type activity (Fig. 4C) . The threshold 380 concentration required to trigger detectable activity was only marginally increased. Fitting the 381 normalised activities with a dose--response curve produced identical results for both strains (Fig.  382   S1C ). This suggests that BcrC overproduction led to an overall decrease in BceAB activity, but had no 383 effect on the transporter's sensitivity to the substrate. Also consistent with a more global effect of 384 BcrC overproduction on cell physiology, was the observation that BceAB activity was similarly 385 reduced when mersacidin and deoxy--actagardine B were tested (Fig. 4D&E) . Likewise, the activity of 386 PsdAB using nisin as substrate was also reduced (Fig. 4F) . It therefore appears that overproduction of 387 BcrC did not have the desired effect of solely reducing the UPP pool in the cell, but instead led to 388 wider--ranging changes that affected either multiple stages of the lipid II cycle, explaining similar 389 effects on bacitracin and lipid II--binding AMPs, or impeded the mechanical functions of the 390 membrane--embedded transporters to reduce their overall activity. Without further knowledge on 391 the precise cellular effects of BcrC overproduction it is difficult to interpret these results. However, 392 while they do not further support our hypothesis that BceAB recognises its substrate AMP as a 393 complex with the cellular target, they also do not disprove it. 394 395
Accumulation of C 35 --PP (HPP) does not inhibit BceAB activity. 396
In addition to the theories on bacitracin import, export or inactivation by BceAB--type transporters, a 397 drastically different mechanism has been proposed where BceAB could protect the cell from 398 bacitracin by flipping UPP from the outer leaflet of the membrane to the inner face, thereby 399 shielding it from the AMP (14). This hypothesis was based on the observation that accumulation of 400 the C 35 isoprenoid heptaprenyl diphosphate (HPP) in the membrane sensitises the cell to bacitracin. 401
HPP was hypothesised to act as a competitive inhibitor of BceAB and to reduce its transport activity 402 (14). To explore this hypothesis further, we next tested the effect of HPP accumulation on BceAB 403 activity, using the luciferase--based assay described above. Accumulation of HPP can be created by 404 manipulations of the isoprenoid biosynthesis pathway (14), specifically via deletion of ytpB, which 405 encodes a tetraprenyl--beta--curcumene synthase (Sato et al., 2011) , and simultaneous limitation of 406 the activity of MenA, a key enzyme in the menaquinone pathway (Kingston et al., 2014) . The menA 407 gene is essential, but a reduction in enzymatic activity can be achieved by growth in tryptophan--408 limited conditions (14). Therefore, to determine whether BceAB activity is inhibited by HPP 409 accumulation, we tested BceAB activity in a ΔytpB ΔmenA deletion strain that carried an ectopic 410 IPTG--inducible copy of menA (SGB929, based on HB13438 (14)) and was grown in a tryptophan--411 limited defined medium without addition of IPTG. 412
Interestingly, the threshold bacitracin concentration required to trigger transport, as well as the 413 activity at peak stimulation were indistinguishable between the two strains, showing that HPP 414 accumulation did not affect BceAB activity (Fig. 5 ). To confirm that our strategy had led to the 415 desired HPP accumulation, we tested the bacitracin sensitivity of both strains. The MIC decreased 416 from 173±12 μg ml --1 in the wild type to 120 μg ml --1 in the mutant strain, in line with the previously 417 reported increased susceptibility upon HPP accumulation (14) . Based on these results, we concluded 418 that the increased bacitracin sensitivity was not due to direct inhibition of BceAB activity by HPP. 419
Instead, our interpretation is that BceAB likely cannot distinguish between UPP--BAC and HPP--BAC. 420
Bacitracin was shown to tightly interact with the pyrophosphate group and only the first isoprenoid 421 unit of its substrate, based on its co--crystal structure with the C 10 isoprenoid geranyl pyrophosphate 422 (32). It is therefore expected that HPP will also serve as a bacitracin target in the cell, and its 423 accumulation will lead to the simultaneous presence of both UPP--BAC and HPP--BAC complexes. In 424 the context of our findings above that UPP--BAC -and by analogy also HPP--BAC -is the likely 425 physiological substrate of BceAB, it is plausible that either complex will drive BceAB activity. Hence, 426 accumulation of HPP did not affect the net transport activity. However, HPP cannot substitute for 427 UPP in the lipid II cycle. Any activity of BceAB invested in the removal of bacitracin from HPP is 428 therefore futile with respect to resistance, which can explain the increased bacitracin sensitivity 429 observed upon HPP accumulation. Taking together our findings with the previous detailed study of 430 the effects of HPP accumulation on bacitracin resistance (14), a model where BceAB removes 431 bacitracin from its cellular targets appears more in line with the available experimental evidence 432 than a UPP--flipping mechanism. Furthermore, as mentioned, BceAB also confers resistance against 433 lipid II--binding AMPs, namely mersacidin, actagardine and the fungal defensin plectasin (8, 36) . For 434 these compounds, it is difficult to envisage a flipping mechanism as an effective strategy to shield 435 the target from AMP access, because import of lipid II runs counter the process of cell wall 436 biosynthesis, where peptidoglycan precursors are required on the surface of the membrane. 437 438 CONCLUDING REMARKS.
439
In this study, we set out to address the much--debated question on the mode--of--action of BceAB--440 type resistance systems and how a transporter may be used to protect the cell from antibiotics that 441 have targets on the cell surface. The balance of evidence presented here and in the literature 442 appears to be in clear favour of BceAB acting as a 'hydrophobic vacuum cleaner', which is in line with 443 the mechanotransmission mechanism proposed for Type VII superfamily ABC systems (30, 31) . In 444 this model, BceAB specifically recognises its substrate AMPs in complex with their respective cellular 445 target, here experimentally tested for UPP--BAC. ATP hydrolysis in the cytoplasm then provides the 446 required energy to break the interaction between bacitracin and UPP on the cell surface. This is not 447 a novel concept in a transporter, because the human cholesterol transporter ABCG5/8 employs a 448 similar mechanism to remove cholesterol from the cytoplasmic membrane of hepatocytes, using the 449 energy from ATP--hydrolysis to break the interactions between cholesterol and membrane 450 phospholipids (37). In the case of BceAB, a shift in equilibrium from target--bound AMP to free AMP 451 can be achieved if the transporter has a low affinity to the free antibiotic and therefore releases it as 452 soon as it is removed from the target. Given the substantial conformational change of bacitracin and 453 other peptides between the free and target--bound forms (1, 38--40) , this seems entirely plausible. In 454 support of this idea, we have only been able to show binding of bacitracin by the entire detergent--455 solubilised transporter, where UPP may have been co--purified (6), but never with its isolated 456 extracellular domain that provides substrate specificity in BceAB--like systems (41) and therefore is 457 thought to contain the ligand binding site (own unpublished data). 458
How then does a simple shift in equilibrium confer the high level of resistance that is the hallmark of 459 BceAB--like transporters? For one, there is ample evidence that the LanFEG--type transporters of AMP 460 producing bacteria work by exactly such a mechanism to provide effective protection from the self--461 produced AMP (19, 20, 28, 29) . Moreover, a similar principle, albeit not on the cell surface, is seen in 462 resistance against tetracyclines, a group of antibiotics that target the bacterial ribosome. Here, 463 ribosomal protection proteins like Tet(O) and Tet(M) were shown to actively release tetracycline 464 from the ribosome in a GTP--driven manner (42, 43) . This mechanism effectively increases the 465 dissociation rate of tetracycline and secures continued protein synthesis (44). Interestingly, another 466 resistance system that protects ribosomal function from antibiotic attack is a group of proteins 467 referred to as Antibiotic Resistance ATP--Binding Cassette--F (ARE ABC--F). While originally annotated 468 as transporters, these proteins lack any transmembrane segments and instead act by modulating the 469 binding affinity between antibiotics and the ribosome, thus effectively dislodging the drugs (45, 46) . 470
This mode of resistance has been collectively termed 'target protection', and generally involves the 471 direct release of a cellular target from the inhibitory action of the antibiotic (46, 47) . Target 472 protection has been reported for the ribosome and DNA replication (48--50), but to our knowledge 473 no example has been described to date for protection of cell wall synthesis. We now propose that 474
BceAB--type transporters act by target protection of the lipid II cycle. By physically freeing UPP from 475 the grip of bacitracin (or analogously, freeing lipid II from lantibiotics), BceAB ensures that the 476 affected enzyme (UPP--phosphatase or PG transglycosylases, respectively) can catalyse the following 477 step of cell wall synthesis, enabling the cycle to continue at least for one more round before the 478 antibiotic can re--bind its target. Importantly, to our knowledge this mode of action is in agreement 479 with all experimental data currently available on BceAB--like systems. Recognition of target--AMP 480 complexes -rather than the free peptides -offers an explanation for the seemingly random 481 substrate specificity of BceAB--like systems (8, 51), where the specificity determinant likely only 482 becomes apparent in the antibiotic--target complex. It also explains the observations on reduced 483 resistance upon over--production of HPP in the cell, where some of BceAB's transport activity is likely 484 invested in the futile removal of bacitracin from HPP rather than UPP (14). And it is consistent with 485 the data reported here and previously (9, 23) that the factor determining transport activity of BceAB 486 is the concentration of UPP--BAC complexes in the cell. Target protection of cell wall synthesis also 487 offers a plausible explanation for the use of transporters in resistance against cell wall--active 488 antibiotics in Gram--positive bacteria. Whereas the outer membrane of Gram--negative 489 microorganisms creates a discrete compartment, and transporters can be used to change a 490 compound's concentration in this space, Gram--positive bacteria lack an equivalent structure. It will 491 be interesting to explore if other transport systems in these bacteria operate by a similar mechanism 492 to protect the cell wall synthesis machinery from antibiotic attack. 493 system. The transporter BceAB confers resistance against bacitracin (BAC), which acts by binding its 649 cellular target UPP. The different debated mechanisms for resistance by BceAB are indicated by 650 dashed arrows (see text for details). Flux--sensing communicates the transport activity of BceAB to 651 the kinase BceS (red wave arrow), causing activation of BceR, which induces transcription from the 652 target promotor P bceA . This results in increased production of BceAB, and therefore adjusted levels of 653 resistance. As signalling is directly proportional to BceAB activity, we can use the target promotor 654 P bceA fused to a luciferase reporter to monitor transport activity. TCS, genes encoding the two--655 were incubated with 5 μg ml --1 bacitracin for 30 min. The biologically active bacitracin remaining in 667 the supernatant after incubation was quantified using a bio--assay. Data are shown as mean ± 668 standard deviation of at least three biological replicates. One--way ANOVA analysis did not show 669 significant differences between samples. 670 BceAB activity were fitted on normalised data of the WT (SGB73) and ∆bcrC mutant (A, SGB649), or 713
BcrC overproduction strain (C, SGB758). To obtain the best fit of experimental data a non--linear fit 714 with variable slope was chosen. Statistical analyses of the log(EC 50 ) values using the in--build non--715 linear regression comparison of GraphPad Prism7 showed a significant difference between the WT 716 and ∆bcrC mutant (****: p < 0.0001), but no difference between WT and BcrC overproduction strain 717 (p = 0.73). B: BceAB activity was tested in wild--type (SGB218) and ∆bcrC strains (SGB677), in which 718
BceAB production was uncoupled from its native regulation. Expression of bceAB was induced by 719 addition of 0.2 % (w/v) xylose. All data are shown as mean ± standard deviation of at least three 720 biological replicates. 721 TABLES 722 Flux--sensing communicates the transport activity of BceAB to the kinase BceS (red wave arrow), causing activation of BceR, which induces transcription from the target promotor P bceA . This results in increased production of BceAB, and therefore adjusted levels of resistance. As signalling is directly proportional to BceAB activity, we can use the target promotor P bceA fused to a luciferase reporter to monitor transport activity. TCS, genes encoding the two--component regulatory system BceRS; ABC, genes encoding the resistance transporter BceAB. B: Using luciferase activity as a proxy, BceAB activity of wild--type B. subtilis W168 carrying the P bceA --lux reporter fusion (WT, SGB73) was determined following 25--35 min challenge of exponentially growing cells with sub-inhibitory concentrations of bacitracin. All data are depicted as mean ± standard deviation of at least three biological replicates. C: Binding reaction between free bacitracin and its cellular target UPP. The change in concentration of UPP--bacitracin complexes (UPP--BAC) through manipulation of either bacitracin or UPP concentrations is indicated by bold font and upward--facing arrows.
Fig.2:
Bacitracin is neither imported nor inactivated by BceAB. Cell suspensions of OD 600 = 10 of B. subtilis W168 (WT) and an isogenic ΔbceAB mutant (TMB035), as well as a buffer control (No cells) were incubated with 5 μg ml --1 bacitracin for 30 min. The biologically active bacitracin remaining in the supernatant after incubation was quantified using a bio--assay. Data are shown as mean ± standard deviation of at least three biological replicates. One--way ANOVA analysis did not show significant differences between samples.
Fig. 3: Accumulation of UPP increases transport activity at low bacitracin concentrations, but does not affect activity on lipid II binding AMPs. A, B:
Pool levels of lipid II cycle intermediates, as predicted by mathematical modelling, are indicated by the relative size of blue bubbles, and numbers of molecules per cell for each intermediate are given. The rate of peptidoglycan (PG) synthesis is shown in molecules of precursor incorporated per minute. The thickness of the arrow for de novo UPP synthesis reflects the previously described homeostatic increase in lipid carrier synthesis upon bcrC deletion (23). A, wild type; B, bcrC deletion mutant. C, D, E, F: Effect of UPP accumulation on transport activity in vivo. As a proxy for transport, luminescence activities of P bceA --lux (C, D, E) or P psdA --lux (F) reporter strains were determined 25--35 min following challenge of exponentially growing cells with varying concentrations of AMPs as indicated. Each panel shows the results for one AMP given below the x--axis. Dark bars show results in the wild--type background (SGB73 or SGB74), lighter bars in the isogenic ΔbcrC background (SGB649 or SGB681). Data are shown as mean ± standard deviation of at least three biological replicates. The increased activity seen in the ΔbcrC background compared to wild type was tested for statistical significance using two--sided t--tests with post--hoc Bonferroni--Dunn correction for multiple comparisons (****: p < 0.0001, ***: p < 0.001, **: p < 0.01, *: 0.01 < p < 0.05). As a proxy for transport, luminescence activities of P bceA --lux (C, D, E) or P psdA --lux (F) reporter strains were determined 25--35 min following challenge of exponentially growing cells with varying concentrations of AMPs as indicated. Each panel shows the results for one AMP given below the x--axis. Dark bars show results in the wild--type background (SGB73 or SGB74), lighter bars in a strain overproducing BcrC (SGB758 or SGB974). Data are shown as mean ± standard deviation of at least three biological replicates. Tests for statistical significance of differences in activity in the overproduction versus wild--type backgrounds were done by two--sided t--test with post--hoc Bonferroni--Dunn correction for multiple comparisons (****: p < 0.0001, ***: p < 0.001, **: p < 0.01, *: 0.01 < p < 0.05).
A WT B High BcrC levels
C D E F Fig. 5 : Accumulation of HPP does not inhibit BceAB activity. Transport activities, using luciferase activity of the P bceA --lux reporter as a proxy, were determined for the WT (SGB927, dark grey) and a HPP accumulation strain (∆ytpB ∆menA amyE::P spac(hy) --menA, SGB929, light grey) grown in MCSE minimal medium, 25--35 minuts following exposure to varying bacitracin concentrations. Data are shown as mean ± standard deviation of at least three biological replicates. Two--sided t--tests with post--hoc Bonferroni--Dunn correction for multiple comparisons did not show any significant difference between the wild--type and the HPP accumulation strain.
Fig. S1
: Bacitracin dose response behaviour of BceAB. A&C: Bacitracin dose response curves of BceAB activity were fitted on normalised data of the WT (SGB73) and ∆bcrC mutant (A, SGB649), or BcrC overproduction strain (C, SGB758). To obtain the best fit of experimental data a non-linear fit with variable slope was chosen. Statistical analyses of the log(EC 50 ) values using the in-build non--linear regression comparison of GraphPad Prism7 showed a significant difference between the WT and ∆bcrC mutant (****: p < 0.0001), but no difference between WT and BcrC overproduction strain (p = 0.73). B: BceAB activity was tested in wild--type (SGB218) and ∆bcrC strains (SGB677), in which BceAB production was uncoupled from its native regulation. Expression of bceAB was induced by addition of 0.2 % (w/v) xylose. All data are shown as mean ± standard deviation of at least three biological replicates.
